Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II One-arm Open-label Neoadjuvant Study of Pembrolizumab in Combination With Nab-paclitaxel Followed by Pembrolizumab in Combination With Epirubicin and Cyclophosphamide in Patients With Triple Negative Breast Cancer

NCT03289819 is registered in ClinicalTrials.gov with Institut fuer Frauengesundheit as lead sponsor.

NCT NCT03289819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03289819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II One-arm Open-label Neoadjuvant Study of Pembrolizumab in Combination With Nab-paclitaxel Followed by Pembrolizumab in Combination With Epirubicin and Cyclophosphamide in Patients With Triple Negative Breast Cancer
Lead sponsor
Institut fuer Frauengesundheit
Phase
Phase 2
Overall status
Completed
Start date
March 23, 2018
Completion date
January 22, 2021
Enrollment
53 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

malignant neoplasm of breast